.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Deloitte
Johnson and Johnson
Argus Health
Teva
Cipla
Queensland Health
QuintilesIMS
Healthtrust

Generated: July 21, 2017

DrugPatentWatch Database Preview

Olsalazine sodium - Generic Drug Details

« Back to Dashboard

What are the generic sources for olsalazine sodium and what is the scope of olsalazine sodium patent protection?

Olsalazine sodium
is the generic ingredient in one branded drug marketed by Mylan Speciality Lp and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for olsalazine sodium. Three suppliers are listed for this compound.

Summary for Generic Name: olsalazine sodium

Tradenames:1
Patents:1
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packagers: see list3
Bulk Api Vendors: see list35
Clinical Trials: see list2,354
Patent Applications: see list1,659
Therapeutic Class:Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:olsalazine sodium at DailyMed

Pharmacology for Ingredient: olsalazine sodium

Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp
DIPENTUM
olsalazine sodium
CAPSULE;ORAL019715-001Jul 31, 1990RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: olsalazine sodium

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp
DIPENTUM
olsalazine sodium
CAPSULE;ORAL019715-001Jul 31, 19904,559,330► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Fish and Richardson
Moodys
Fuji
Dow
Medtronic
Argus Health
Colorcon
Julphar
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot